All In Biotech

Drug Trial Radar · NCT00533481

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Last checked: Nov 20, 2026Latest source record: Sep 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 497 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

497

Actual

Start

Feb 2004

Primary completion

Dec 2004

Study completion Dec 2004

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Conditions

  • Obesity

Interventions

  • MK0557Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.